TD Cowen Keeps Their Hold Rating on GlaxoSmithKline (GSK)
TD Cowen analyst Steve Scala maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of $45.00. The ...
GSK Stock Declines 20% in 3 Months: Should You Buy, Sell or Hold?
Though GSK is definitely not the best large-cap drugmaker to have in one's portfolio, we believe there is potential for its ...
Zacks.com on MSN23h
Biotech Stock Roundup: BIOA Down on Study Update, QURE, CRDF Gain on Study Data & More
It was a busy week in the biotech sector with lots of data readouts. This apart, the key regulatory updates and pipeline news ...
The New York Times22h
New York Times - Top Stories
Police Say Suspect’s Notebook Described Motive for C.E.O. Killing The man who has been charged with killing Brian Thompson was found with a notebook that detailed plans for the shooting ...
The New York Times17h
New York Times - Top Stories
Suspect in C.E.O.’s Killing Fights Extradition to New York Police say suspect in the United Healthcare killing saw himself as a hero fighting corruption. The suspect had discussed a series of ...